NOVACOR® LVAS PATIENT INFORMATION BOOKLET:

Download our Novacor® LVAS Patient Information Guide for answers to frequently asked questions:

Novacor® LVAS
Patient Information Booklet

FAST FACTS:

According to the American Heart Association:

• 2,016 and 2,127 heart transplants were performed in the United States in 2004 and 2005, respectively.
• Heart failure affects nearly five million Americans of all ages and is responsible for more hospitalizations than all forms of cancer combined.
• Over 550,000 new cases of heart failure will be diagnosed in the next year.

STAY INFORMED:

For an easy to read and informative description of various types of heart problems and disease and their causes, we recommend this report from the American Heart Association:

Heart and Stroke Facts

Overview

Center Locator

Life with a WorldHeart VAD

Patients

WorldHeart is presently focused on starting US clinical trials in the second half of 2009 with its next-generation Levacor VAD for use as a bridge to transplant. Watch for exciting new announcements and information related to this event in the next few months!

WorldHeart's pioneering first-generation Novacor LVAS has been clinically used since 1984, having served more than 1800 patients in North America, Europe and Japan. In 2008, its sale was discontinued worldwide. WorldHeart and its Novacor clinical centers continue to support patients who are still using the Novacor LVAS.

Note: The information contained within this web site is not intended to substitute for professional advice from doctors or medical practitioners. Rather, it is a resource to improve understanding of heart failure and how it can be treated.